Action Pharma focuses its strategy and appoints a new CEO
The Board of Directors of Action Pharma has decided to focus the Company’s strategy on partnering of its lead projects and to explore the opportunity of strengthening the Company through M&A or consolidation. To drive this process the Board of Directors has appointed Ingelise Saunders as new CEO of Action Pharma. Søren Nielsen, former CEO, takes up the position as Chief Operating Officer (COO) and continues as part of Action Pharma’s executive management group.
Ingelise Saunders has more than 30 years of experience in the international pharmaceutical and biotech industry. Before joining Action Pharma, she was President and CEO of ACE BioSciences, Denmark, for five years. Prior to that, Ms. Saunders was for three years CEO of Celltech Pharmaceuticals Plc, the UK, with global commercial responsibility, and spent 16 years with Novo Nordisk in senior executive management positions, both in Denmark and in the UK.
“With two lead programs in clinical phase I and II, which exploits a new mode of action, there is significant partnering and M&A interest in Action Pharma. I am excited to get involved at this important stage of Action Pharma’s development, and I look forward to working with the Action Pharma team and the Board of Directors to take the Company to the next phase”, says Ingelise Saunders.
Other news from the department people
